Atherosclerotic Cardiovascular Disease (ASCVD), Benign Prostatic Hypertrophy (BPH)
Conditions
Brief summary
To assess the impact of 5-alpha reductase inhibitors (5-ARIs) on the incidence of atherosclerotic cardiovascular disease (ASCVD) in patients with benign prostatic hyperplasia (BPH).
Interventions
Building on prior studies, drug exposure was defined as receiving 5-ARIs on at least two separate occasions, with an interval of no more than 180 days between prescriptions. Based on exposure status, the cohort was stratified into two groups.
Sponsors
Chinese PLA General Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
MALE
Age
45 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients diagnosed with BPH or users of 5-ARIs
Exclusion criteria
* individuals who had cancer prior to the start of follow-up and those with pre-existing ASCVD
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Atherosclerotic Cardiovascular Disease | Started taking 5α-reductase inhibitors until December 1, 2022 | While both CVD and ASCVD are composite disease categories, CVD encompasses a broader range of cardiovascular and cerebrovascular conditions. To ensure homogeneity in disease classification, we focused on ASCVD, which primarily refers to atherosclerosis-related cardiovascular and cerebrovascular diseases, including ischemic heart disease (IHD) and cerebrovascular disease (CeVD) |
Outcome results
None listed